Brief: Intelgenx Announces FDA Acceptance New Drug Application Resubmission For Rizaport
20/11/2018 13:14
Nov 20 (Reuters) - Intelgenx Technologies Corp IGX.V :
* INTELGENX ANNOUNCES FDA’S ACCEPTANCE OF RESUBMISSION OF
NEW DRUG
APPLICATION FOR RIZAPORT®
* INTELGENX TECHNOLOGIES - PDUFA GOAL DATE OF APRIL 1, 2019
FOR
RIZAPORT
* INTELGENX TECHNOLOGIES CORP - FDA HAS ASSIGNED PDUFA GOAL
DATE
FOR COMPLETION OF REVIEW OF RIZAPORT NDA OF APRIL 1, 2019
Source text for Eikon: ID:nGNX2LHXq6
Further company coverage: IGX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA